Cited by 372Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 380 of the 380 references it cites were found in a registry or an index.

Tau-targeting therapies for Alzheimer disease: current status and future directions

Open access

Congdon, Erin E., Ji, Changyi, Tetlow, Amber M., Jiang, Yixiang, Sigurdsson, Einar M.·2023·Nature Reviews Neurology

DOI 10.1038/s41582-023-00883-2PMC PMC10965012

Open this paper in CoChat — free account Open PDF

Abstract

Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain, with associated loss of synapses and neurons, which eventually results in dementia. Many of the early attempts to develop treatments for AD focused on Aβ, but a lack of efficacy of these treatments in terms of slowing disease progression led to a change of strategy towards targeting of tau pathology. Given that tau shows a stronger correlation with symptom severity than does Aβ, targeting of tau is more likely to be efficacious once cognitive decline begins. Anti-tau therapies initially focused on post-translational modifications, inhibition of tau aggregation and stabilization of microtubules. However, trials of many potential drugs were discontinued because of toxicity and/or lack of efficacy. Currently, the majority of tau-targeting agents in clinical trials are immunotherapies. In this Review, we provide an update on the results from the initial immunotherapy trials and an overview of new therapeutic candidates that are in clinical development, as well as considering future directions for tau-targeting therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41582-023-00883-2

Cites

380 of 380 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Items 201–380 of 380

Tau Phosphorylation by cdk5 and Fyn in Response to Amyloid Peptide Aβ25–35: Involvement of Lipid Rafts
Hernandez, P., Lee, G., Sjoberg, M., & Maccioni, R. B. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0933 · Cited by 107
Advances and considerations in AD tau-targeted immunotherapy
Bittar, A., Bhatt, N. N., & Kayed, R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104707 · Cited by 106
Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors
Hintersteiner, B., Lingg, N., Zhang, P., Woen, S., Hoi, K. M., Stranner, S., Wiederkum, S., Mutschlechner, O., Schuster, M., Loibner, H., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1225642 · Cited by 105
Improving the solubility of anti‐LINGO‐1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis
Pepinsky, R. B., Silvian, L. F., Berkowitz, S. A., Farrington, G., Lugovskoy, A. A., Walus, L. R., Eldredge, J. K., Capili, A. D., Mi, S., Graff, C. P., et al. (2010) · Protein Science · doi:10.1002/pro.372 · Cited by 103
Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging
Flores, J., Noël, A., Foveau, B., Beauchet, O., & LeBlanc, A. C. (2020) · Nature Communications · doi:10.1038/s41467-020-18405-9 · Cited by 103
Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration
Bussière, T., Hof, P. R., Vanbesien-Mailliot, C., Brown, C., Caillet‐Boudin, M., Perl, D. P., Buée, L., & Delacourte, A. (1999) · Acta Neuropathologica · doi:10.1007/s004010050978 · Cited by 102
p35/Cdk5 pathway mediates soluble amyloid‐β peptide‐induced tau phosphorylation in vitro
Town, T., Zolton, J., Shaffner, R., Schnell, B., Crescentini, R. M., Wu, Y., Zeng, J., DelleDonne, A., Obregon, D. F., Tan, J., et al. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10299 · Cited by 102
Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model
Chatterjee, D., Bhatt, M. A., Butler, D., Genst, E. D., Dobson, C. M., Messer, A. C., & Kordower, J. H. (2018) · npj Parkinson s Disease · doi:10.1038/s41531-018-0062-4 · Cited by 101
Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation
Igawa, T., Haraya, K., & Hattori, K. (2016) · Immunological Reviews · doi:10.1111/imr.12392 · Cited by 100
Targeting selective autophagy by AUTAC degraders
Takahashi, D., & Arimoto, H. (2020) · Autophagy · doi:10.1080/15548627.2020.1718362 · Cited by 100
The potential role of tau protein O-glycosylation in Alzheimer's disease
Robertson, L. A., Moya, K. L., & Breen, K. C. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6505 · Cited by 99
Role of heavy chain constant domains in antibody-antigen interaction. Apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains
Cooper, L. J. N., Shikhman, A. R., Glass, D. D., Kangisser, D., Cunningham, M. W., & Greenspan, N. S. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.6.2231 · Cited by 99
CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
Horie, K., Barthélemy, N. R., Spina, S., VandeVrede, L. A., He, Y., Paterson, R. W., Wright, B. A., Day, G. S., Davis, A. A., Karch, C. M. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02075-9 · Cited by 99
Variable-Region-Identical Antibodies Differing in Isotype Demonstrate Differences in Fine Specificity and Idiotype
Torres, M., May, R. J., Scharff, M. D., & Casadevall, A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.2132 · Cited by 98
Structure and Mechanism of Action of Tau Aggregation Inhibitors
Cisek, K. K., Cooper, G., Huseby, C. J., & Kuret, J. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666141107150331 · Cited by 98
Astrocytes in Tauopathies
Reid, M. J., Beltran-Lobo, P., Johnson, L., Perez‐Nievas, B. G., & Noble, W. J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.572850 · Cited by 98
Current Status of Clinical Trials on Tau Immunotherapies
Ji, C., & Sigurdsson, E. M. (2021) · Drugs · doi:10.1007/s40265-021-01546-6 · Cited by 96
Methylene Blue Reduced Abnormal Tau Accumulation in P301L Tau Transgenic Mice
Hosokawa, M., Arai, T., Masuda‐Suzukake, M., Nonaka, T., Yamashita, M., Akiyama, H., & Hasegawa, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052389 · Cited by 95
Can immunoglobulin C(H)1 constant region domain modulate antigen binding affinity of antibodies?
Pritsch, O., Hudry-Clergeon, G., Buckle, M., Pétillot, Y., Bouvet, J., Gagnon, J., & Dighiero, G. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119033 · Cited by 95
Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I
Andoh, T., & Kuraishi, Y. (2003) · The FASEB Journal · doi:10.1096/fj.02-1169fje · Cited by 94
Isotype Can Affect the Fine Specificity of an Antibody for a Polysaccharide Antigen
McLean, G. R., Torres, M., Elguezábal, N., Nakouzi, A. S., & Casadevall, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.3.1379 · Cited by 94
Purkinje Cell Death After Uptake of Anti-Yo Antibodies in Cerebellar Slice Cultures
Greenlee, J., Clawson, S. A., Hill, K. E., Wood, B., Tsunoda, I., & Carlson, N. G. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181f0c82b · Cited by 90
A randomized, single ascending dose study of intravenous BIIB092 in healthy participants
Qureshi, I., Tirucherai, G., Ahlijanian, M. K., Kolaitis, G., Bechtold, C. M., & Grundman, M. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.007 · Cited by 90
Regulation of Antigen Export to the Cytosol During Cross-Presentation
Gros, M., & Amigorena, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00041 · Cited by 90
Tau immunotherapies: Lessons learned, current status and future considerations
Sandusky-Beltran, L. A., & Sigurdsson, E. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108104 · Cited by 90
TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
Fitzgerald, D. P., Emerson, D. L., Qian, Y., Anwar, T., Liewehr, D. J., Steinberg, S. M., Silberman, S., Palmieri, D., & Steeg, P. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0061 · Cited by 89
VPS13A, a closely associated mitochondrial protein, is required for efficient lysosomal degradation
Muñoz‐Braceras, S., Tornero-Écija, A., Vincent, O., & Escalante, R. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.036681 · Cited by 87
Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases
Hickman, D. T., López-Deber, M. P., Ndao, D. M., Silva, A. B., Nand, D., Pihlgren, M., Giriens, V., Madani, R., St-Pierre, A., Karastaneva, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.186338 · Cited by 84
Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models
Mukadam, A. S., Miller, L. V. C., Smith, A. E., Vaysburd, M., Sakya, S. A., Sanford, S., Keeling, S., Tuck, B. J., Katsinelos, T., Green, C., et al. (2023) · Science · doi:10.1126/science.abn1366 · Cited by 84
Isotype Switching Increases Efficacy of Antibody Protection against Cryptococcus neoformans Infection in Mice
Yuan, R. R., Spira, G., Oh, J. S., Paizi, M., Casadevall, A., & Scharff, M. D. (1998) · Infection and Immunity · doi:10.1128/iai.66.3.1057-1062.1998 · Cited by 83
Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments
Butler, D. C., & Messer, A. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029199 · Cited by 81
Bilateral Injections of Amyloid-β 25-35 into the Amygdala of Young Fischer Rats: Behavioral, Neurochemical, and Time Dependent Histopathological Effects
Sigurdsson, E. M., Lee, J. M., Dong, X.-W., Hejna, M. J., & Lorens, S. A. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00154-1 · Cited by 81
α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice
Butler, Y. R., Liu, Y., Kumbhar, R., Zhao, P., Gadhave, K., Wang, N., Li, Y., Mao, X., & Wang, W. (2022) · Nature Communications · doi:10.1038/s41467-022-31787-2 · Cited by 80
Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcγ-receptor binding and functional lysosomes
Andersson, C. R., Falsig, J., Stavenhagen, J. B., Christensen, S., Kartberg, F., Rosenqvist, N., Finsen, B. R., & Pedersen, J. T. (2019) · Scientific Reports · doi:10.1038/s41598-019-41105-4 · Cited by 79
Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment
Wang, J., Kang, G., Yuan, H.-X., Cao, X.-C., Huang, H., & de Marco, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.838082 · Cited by 79
Evidence for neuronal expression of functional Fc (ε and γ) receptors
van der Kleij, H. P. M., Charles, N., Karimi, K., Mao, Y., Foster, J. A., Janssen, L. J., Yang, P. C., Kunze, W., Rivera, J., & Bienenstock, J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.054 · Cited by 78
Potential mechanisms and implications for the formation of tau oligomeric strains
Gerson, J. E., Mudher, A. K., & Kayed, R. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2016.1226251 · Cited by 78
Involvement of Oligodendrocytes in Tau Seeding and Spreading in Tauopathies
Ferrer, I., Aguiló, M., Carmona, M., Andrés‐Benito, P., Torrejón-Escribano, B., Garcia‐Esparcia, P., & del Rı́o, J. A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00112 · Cited by 78
Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD
Robinson, J. L., Yan, N., Caswell, C., Xie, S. X., Suh, E. R., Deerlin, V. M. V., Gibbons, G. S., Irwin, D. J., Grossman, M., Lee, E. B., et al. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz141 · Cited by 78
A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies
Zheng, J., Tian, N., Liu, F., Zhang, Y., Su, J., Gao, Y., Deng, M., Wei, L., Ye, J., Li, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00669-2 · Cited by 78
Neuronal Fc-gamma receptor I mediated excitatory effects of IgG immune complex on rat dorsal root ganglion neurons
Qu, L., Zhang, P., LaMotte, R. H., & Ma, C. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.04.008 · Cited by 77
Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls1
Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179937 · Cited by 76
Phosphorylated tau sites that are elevated in Alzheimer's disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain
Moloney, C. M., Labuzan, S. A., Crook, J. E., Siddiqui, H., Castanedes‐Casey, M., Lachner, C., Petersen, R. C., Duara, R., Graff‐Radford, N. R., Dickson, D. W., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12749 · Cited by 76
A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer’s Disease
Malpas, C. B., Vivash, L. E., Genc, S., Saling, M. M., Desmond, P. M., Steward, C. E., Hicks, R. J., Callahan, J., Brodtmann, A. G., Collins, S. J., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160544 · Cited by 75
Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment
Danis, C., Dupré, E., Zejneli, O., Caillierez, R., Arrial, A., Bégard, S., Mortelecque, J., Eddarkaoui, S., Loyens, A., Cantrelle, F., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.009 · Cited by 75
Passive immunotherapy of tauopathy targeting pSer413‐tau: a pilot study in mice
Umeda, T., Eguchi, H., Kunori, Y., Matsumoto, Y., Taniguchi, T., Mori, H., & Tomiyama, T. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.171 · Cited by 74
The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points.
Kobayashi, H., Le, N., Kim, I. S., Kim, M. K., Pie, J.-E., Drumm, D., Paik, D. S., Waldmann, T. A., Paik, C. H., & Carrasquillo, J. A. (1999) · PubMed · Cited by 73
Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model
Krishnamurthy, P., Deng, Y., & Sigurdsson, E. M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00059 · Cited by 73
Protein phosphatase 2A and tau: an orchestrated ‘Pas de Deux’
Taleski, G., & Sontag, E. (2017) · FEBS Letters · doi:10.1002/1873-3468.12907 · Cited by 71
Isothermal Titration Calorimetry Reveals Differential Binding Thermodynamics of Variable Region-identical Antibodies Differing in Constant Region for a Univalent Ligand
Dam, T. K., Torres, M., Brewer, C. F., & Casadevall, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806473200 · Cited by 70
A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer’s Disease
Sun, H., Zhong, Y., Zhu, X., Liao, H., Lee, J., Chen, Y., Ma, L., Ren, J., Zhao, M., Tu, M., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c10690 · Cited by 70
Tubulin tyrosination regulates synaptic function and is disrupted in Alzheimer’s disease
Peris, L., Parato, J., Qu, X., Soleilhac, J.-M., Lanté, F., Kumar, A., Pero, M. E., Hernández, J. M., Corrao, C., Falivelli, G., et al. (2021) · Brain · doi:10.1093/brain/awab436 · Cited by 70
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ
Butler, D. C., Joshi, S. N., Genst, E. D., Baghel, A. S., Dobson, C. M., & Messer, A. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165964 · Cited by 68
Aggregated SOD1 causes selective death of cultured human motor neurons
Benkler, C., O’Neil, A., Slepian, S., Qian, F., Weinreb, P. H., & Rubin, L. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-34759-z · Cited by 68
Insulin‐like growth factor‐II/mannose‐6‐phosphate receptor: Widespread distribution in neurons of the central nervous system including those expressing cholinergic phenotype
Hawkes, C. A., & Kar, S. (2003) · The Journal of Comparative Neurology · doi:10.1002/cne.10578 · Cited by 67
Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls
Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-189010 · Cited by 67
Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System
Röth, S., Macartney, T., Konopacka, A., Chan, K.-H., Zhou, H., Queisser, M. A., & Sapkota, G. P. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.06.012 · Cited by 67
Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption
Greenlee, J., Burns, J. B., ROSE, J. W., Jaeckle, K. A., & Clawson, S. A. (1995) · Acta Neuropathologica · doi:10.1007/bf00309627 · Cited by 66
Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation
Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., Karussis, D., & Rosenmann, H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.006 · Cited by 66 · cited 1×
“Detrimental effects were seen in early mouse studies that used full-length recombinant tau with strong adjuvants that would never be approved for use in humans 173,174 .”
Background
Cathepsin D expression is decreased in Alzheimer's disease fibroblasts
Urbanelli, L., Emiliani, C., Massini, C., Persichetti, E., Orlacchio, A., Pelicci, G., Sorbi, S., Hasilík, A., Bernardi, G., & Orlacchio, A. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.09.005 · Cited by 66
LiCl Attenuates Thapsigargin-Induced Tau Hyperphosphorylation by Inhibiting GSK-3β In Vivo and In Vitro
Fu, Z., Yang, Y., Song, J., Jiang, Q., Liu, Z.-C., Wang, Q., Zhu, L., Wang, J., & Tian, Q. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100687 · Cited by 65
Immunopositivity for ESCRT-III subunit CHMP2B in granulovacuolar degeneration of neurons in the Alzheimer's disease hippocampus
Yamazaki, Y., Takahashi, T., Hiji, M., Kurashige, T., Izumi, Y., Yamawaki, T., & Matsumoto, M. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.04.038 · Cited by 65
Characterization of tau binding by gosuranemab
Sopko, R., Golonzhka, O., Arndt, J. W., Quan, C., Czerkowicz, J., Cameron, A., Smith, B., Yogapriya, M., Gibbons, G. S., Kim, S., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105120 · Cited by 65
Cis P-tau underlies vascular contribution to cognitive impairment and dementia and can be effectively targeted by immunotherapy in mice
Qiu, C., Albayram, Ö., Kondo, A., Wang, B., Kim, N., Arai, K., Tsai, C.-Y., Bassal, M. A., Herbert, M. K., Washida, K., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7615 · Cited by 65
Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy
Congdon, E. E., Lin, Y., Rajamohamedsait, H. B., Shamir, D. B., Krishnaswamy, S., Rajamohamedsait, W. J., Rasool, S., González‐Calle, V., Levenga, J., Gu, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0126-z · Cited by 64
Antibody RING-Mediated Destruction of Endogenous Proteins
Ibrahim, A. F. M., Shen, L., Tatham, M. H., Dickerson, D. R., Prescott, A. R., Abidi, N., Xirodimas, D. P., & Hay, R. T. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.032 · Cited by 64
Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease
Tissot, C., Therriault, J., Pascoal, T. A., Chamoun, M., Lussier, F. Z., Savard, M., Mathotaarachchi, S. S., Benedet, A. L., Thomas, E. M., Parsons, M., et al. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12154 · Cited by 63
Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates
Cantrelle, F., Loyens, A., Trivelli, X., Reimann, O., Despres, C., Gandhi, N. S., Hackenberger, C. P. R., Landrieu, I., & Smet‐Nocca, C. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.661368 · Cited by 63
Antibody-DerivedIn VivoImaging of Tau Pathology
Krishnaswamy, S., Lin, Y., Rajamohamedsait, W. J., Rajamohamedsait, H. B., Krishnamurthy, P., & Sigurdsson, E. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2755-14.2014 · Cited by 62
Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures
Greenlee, J., Clawson, S. A., Hill, K. E., Wood, B., Clardy, S. L., Tsunoda, I., Jaskowski, T. D., & Carlson, N. G. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0160-0 · Cited by 62
Neuronal FcγRI mediates acute and chronic joint pain
Wang, L., Jiang, X., Qin, Z. H., Jeon, S., Chen, T., Liu, Y., Kulaga, H. M., Reed, R. R., Dong, X., Caterina, M. J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128010 · Cited by 62
Targeting tauopathy with engineered tau-degrading intrabodies
Gallardo, G., Wong, C. H. Y., Hernandez, S. M. R., Mann, C. N., Lin, K., Leyns, C. E. G., Jiang, H., & Holtzman, D. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0340-6 · Cited by 61
Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
Expression of insulin-like growth factor-II (IGF-II) and IGF-II/mannose-6-phosphate receptor in the rat hippocampus: an in situ hybridization and immunocytochemical study.
Couce, M., Weatherington, A., & McGinty, J. F. (1992) · Endocrinology · doi:10.1210/endo.131.4.1396308 · Cited by 60
Carbon-13 NMR study of switch variant anti-dansyl antibodies: antigen binding and domain-domain interactions
Kato, K., Matsunaga, C., Odaka, A., Yamato, S., Takaha, W., Shimada, I., & Arata, Y. (1991) · Biochemistry · doi:10.1021/bi00240a033 · Cited by 59
Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice
Vitale, F., Giliberto, L., Ruiz, S., Steslow, K., Marambaud, P., & d’Abramo, C. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0585-2 · Cited by 59
Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
Oakley, S. S., Maina, M. B., Marshall, K. E., Al‐Hilaly, Y. K., Harrington, C., Wischik, C. M., & Serpell, L. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.590754 · Cited by 59
AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy
Ising, C., Gallardo, G., Leyns, C. E. G., Wong, C. H., Jiang, H., Stewart, F., Koscal, L. J., Roh, J., Robinson, G. O., Remolina Serrano, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162125 · Cited by 57
Open‐Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy
VandeVrede, L. A., Dale, M. L., Fields, S., Frank, M., Hare, E. B., Heuer, H. W., Keith, K., KOESTLER, M. E., Ljubenkov, P. A., McDermott, D., et al. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12940 · Cited by 57
Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy
Congdon, E. E., Chukwu, J. E., Shamir, D. B., Deng, J., Ujla, D., Sait, H. B. R., Neubert, T. A., Kong, X., & Sigurdsson, E. M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.033 · Cited by 56
TSC1 loss increases risk for tauopathy by inducing tau acetylation and preventing tau clearance via chaperone-mediated autophagy
Alquezar, C., Schoch, K. M., Geier, E. G., Ramos, E. M., Scrivo, A., Li, K. H., Argouarch, A. R., Mlynarski, E. E., Dombroski, B., DeTure, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg3897 · Cited by 56
The contribution of altered neuronal autophagy to neurodegeneration
Filippone, A., Esposito, E., Mannino, D., Lyssenko, N., & Praticò, D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108178 · Cited by 55
Intraneuronal IgG in the central nervous system
Fabian, R. H., & Ritchie, T. C. (1986) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(86)90150-4 · Cited by 53
Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology
Rueli, R. H., Torres, D. J., Dewing, A. S. T., Kiyohara, A. C. P., Barayuga, S. M., Bellinger, M. T., Uyehara‐Lock, J. H., White, L. R., Moreira, P. I., Berry, M. J., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151208 · Cited by 53
Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: Focus on davunetide (NAP)
Magen, I., & Gozes, I. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.10.011 · Cited by 52
β-Amyloid peptide toxicity in organotypic hippocampal slice culture involves Akt/PKB, GSK-3β, and PTEN
Nassif, M., Hoppe, J. B., Santin, K., Frozza, R. L., Zamin, L. L., Simão, F., Horn, A. P., & Salbego, C. G. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.08.008 · Cited by 52
Highly specific and selective anti‐pS396‐tau antibody C10.2 targets seeding‐competent tau
Rosenqvist, N., Asuni, A. A., Andersson, C. R., Christensen, S., Daechsel, J. C. A., Egebjerg, J., Falsig, J., Helboe, L., Jul, P., Kartberg, F., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.005 · Cited by 52
Circular Dichroism reveals evidence of coupling between immunoglobulin constant and variable region secondary structure☆
Markmann, A. J., & Casadevall, A. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.02.018 · Cited by 51
The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies
Xia, Y., Pawar, R. D., Nakouzi, A. S., Herlitz, L., Broder, A. R., Liu, K., Goilav, B., Fan, M., Wang, L., Li, Q., et al. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.06.005 · Cited by 51
CD3 and Immunoglobulin G Fc Receptor Regulate Cerebellar Functions
Nakamura, K., Hirai, H., Torashima, T., Miyazaki, T., Tsurui, H., Xiu, Y., Ohtsuji, M., Lin, Q. S., Tsukamoto, K., Nishimura, H., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01072-06 · Cited by 51
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease
Aillaud, I., & Funke, S. A. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01230-7 · Cited by 51
Phospho-Tau Changes in the Human CA1 During Alzheimer’s Disease Progression
Regalado-Reyes, M., Furcila, D., Hernández, F., Ávila, J., DeFelipe, J., & León‐Espinosa, G. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181263 · Cited by 50
Local and distant histopathological effects of unilateral amyloid-β 25–35 injections into the amygdala of young F344 rats
Sigurdsson, E. M., Lorens, S. A., Hejna, M. J., Dong, X.-W., & Lee, J. M. (1996) · Neurobiology of Aging · doi:10.1016/s0197-4580(96)00169-8 · Cited by 49
Exchanging Murine and Human Immunoglobulin Constant Chains Affects the Kinetics and Thermodynamics of Antigen Binding and Chimeric Antibody Autoreactivity
Torres, M., Fernández‐Fuentes, N., Fiser, A., & Casadevall, A. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001310 · Cited by 49
Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice
Rajamohamedsait, H., Rasool, S., Rajamohamedsait, W., Lin, Y., & Sigurdsson, E. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-17313-1 · Cited by 49
Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immunotherapeutics
Hill, K. E., Clawson, S. A., ROSE, J. W., Carlson, N. G., & Greenlee, J. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-31 · Cited by 46
Characterization of TauC3 antibody and demonstration of its potential to block tau propagation
Nicholls, S. B., DeVos, S. L., Commins, C., Nobuhara, C. K., Bennett, R. E., Corjuc, D. L., Maury, E. A., Eftekharzadeh, B., Akingbade, O., Fan, Z., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177914 · Cited by 46
Tau oligomers mediate aggregation of RNA‐binding proteins Musashi1 and Musashi2 inducing Lamin alteration
Montalbano, M., McAllen, S., Sengupta, U., Puangmalai, N., Bhatt, N. N., Ellsworth, A., & Kayed, R. (2019) · Aging Cell · doi:10.1111/acel.13035 · Cited by 46
Compromised autophagy and mitophagy in brain ageing and Alzheimer’s diseases.
Caponio, D., Veverová, K., Zhang, S.-Q., Shi, L., Wong, G., Vyhnalek, M., & Fang, E. F. (2022) · Aging Brain · doi:10.1016/j.nbas.2022.100056 · Cited by 45
Claw retraction and protraction in the carnivora: Skeletal microvariation in the phalanges of the Felidae
Bryant, H. N., Russell, A. P., Laroiya, R., & Powell, G. L. (1996) · Journal of Morphology · doi:10.1002/(sici)1097-4687(199609)229:3 · Cited by 44
A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor
Han, P., Serrano, G. E., Beach, T. G., Caselli, R. J., Yin, J., Zhuang, N., & Shi, J. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw105 · Cited by 44
Tau immunotherapy is associated with glial responses in FTLD-tau
Kim, B., Mikytuck, B., Suh, E. R., Gibbons, G. S., Deerlin, V. M. V., Vaishnavi, S., Spindler, M., Massimo, L. M., Grossman, M., Trojanowski, J. Q., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02318-y · Cited by 44
Biomarkers in frontotemporal lobar degenerations—Progress and challenges
Hu, W. T., Trojanowski, J. Q., & Shaw, L. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.04.012 · Cited by 42
Nociceptive neuronal Fc-gamma receptor I is involved in IgG immune complex induced pain in the rat
Jiang, H., Shen, X., Chen, Z., Liu, F., Wang, T., Xie, Y., & Ma, C. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.03.001 · Cited by 41
Expression of Fc epsilon receptor I on primary sensory neurons in mice
Andoh, T., & Kuraishi, Y. (2004) · Neuroreport · doi:10.1097/00001756-200409150-00007 · Cited by 40
The constant region affects antigen binding of antibodies to DNA by altering secondary structure
Xia, Y., Markmann, A. J., Eryilmaz, E., Casadevall, A., & Putterman, C. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.04.004 · Cited by 39
Cellular Uptake of α-Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of α-Synuclein and Mediated via Fcγ Receptors
Gustafsson, G., Eriksson, F., Möller, C., da Fonseca, T. L., Outeiro, T. F., Lannfelt, L., Bergström, J. J. E., & Ingelsson, M. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0352-5 · Cited by 38
Increase in α-tubulin modifications in the neuronal processes of hippocampal neurons in both kainic acid-induced epileptic seizure and Alzheimer’s disease
Vu, H. T., Akatsu, H., Hashizume, Y., Setou, M., & Ikegami, K. (2017) · Scientific Reports · doi:10.1038/srep40205 · Cited by 38
Monoclonal full-length antibody against TAR DNA binding protein 43 reduces related proteinopathy in neurons
Pozzi, S., Codron, P., Soucy, G., Renaud, L., Cordeau, P., Dutta, K., Bareil, C., & Julien, J. (2020) · JCI Insight · doi:10.1172/jci.insight.140420 · Cited by 38
Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly
Congdon, E. E., Jiang, Y., & Sigurdsson, E. M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.12.002 · Cited by 38
A critical role for p59fyn in CD2-based signal transduction
Fukai, I., Hussey, R. E., Sunder‐Plaßmann, R., & Reinherz, E. L. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(2000012)30:12 · Cited by 37
IgG Subclass and Heavy Chain Domains Contribute to Binding and Protection by mAbs to the Poly γ-D-glutamic Acid Capsular Antigen of Bacillus anthracis
Hovenden, M., Hubbard, M., AuCoin, D. P., Thorkildson, P., Reed, D. E., Welch, W. H., Lyons, C. R., Lovchik, J. A., & Kozel, T. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003306 · Cited by 36
Fc gamma receptors are expressed in the developing rat brain and activate downstream signaling molecules upon cross-linking with immune complex
Stamou, M., Grodzki, A. C., van Oostrum, M., Wollscheid, B., & Lein, P. J. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1050-z · Cited by 36
Pharmacological Modulators of Tau Aggregation and Spreading
Dominguez‐Meijide, A., Vasili, E., & Outeiro, T. F. (2020) · Brain Sciences · doi:10.3390/brainsci10110858 · Cited by 36
Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation
Žilková, M., Nölle, A., Kováčech, B., Kontseková, E., Weisová, P., Filipčík, P., Škrabana, R., Prčina, M., Hromádka, T., Cehlár, O., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00948-z · Cited by 35
The hippocampal sparing subtype of Alzheimer’s disease assessed in neuropathology and in vivo tau positron emission tomography: a systematic review
Ferreira, D., Mohanty, R., Murray, M. E., Nordberg, A. K., Kantarci, K., & Westman, E. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01471-z · Cited by 35
Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach
Shamir, D. B., Rosenqvist, N., Rasool, S., Pedersen, J. T., & Sigurdsson, E. M. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.013 · Cited by 34
Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity
Congdon, E. E., Pan, R., Jiang, Y., Sandusky‐Beltran, L. A., Dodge, A., Lin, Y., Liu, M., Kuo, M., Kong, X., & Sigurdsson, E. M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104249 · Cited by 33
Autoantibodies to synapsin I sequestrate synapsin I and alter synaptic function
Rocchi, A., Sacchetti, S., Fusco, A. D., Giovedı̀, S., Parisi, B., Cesca, F., Höltje, M., Ruprecht, K., Ahnert‐Hilger, G., & Benfenati, F. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2106-z · Cited by 32
Crosstalk between acetylation and the tyrosination/detyrosination cycle of α-tubulin in Alzheimer’s disease
Hernández, J. M., Parato, J., Sharma, A., Soleilhac, J.-M., Qu, X., Tein, E., Sproul, A. A., Andrieux, A., Goldberg, Y., Moutin, M., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.926914 · Cited by 32
Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging
Wu, Q., Lin, Y., Gu, J., & Sigurdsson, E. M. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.041 · Cited by 31
Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region
Handlogten, M. W., Peng, L., Christian, E. A., Xu, W., Lin, S., Venkat, R. V., Dall’Acqua, W. F., & Ahuja, S. (2020) · mAbs · doi:10.1080/19420862.2020.1779974 · Cited by 31
Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders
Spencer, B. J., Brüschweiler, S., Sealey‐Cardona, M., Rockenstein, E. M., Adame, A., Florio, J. B., Mante, M., Trinh, I., Rissman, R. A., Konrat, R., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1869-0 · Cited by 30
Electrostatic interactions modulate the differential aggregation propensities of IgG1 and IgG4P antibodies and inform charged residue substitutions for improved developability
Heads, J. T., Lamb, R., Kelm, S., Adams, R., Elliott, P., Tyson, K. L., Topia, S., West, S. M., Nan, R., Turner, A. V., et al. (2019) · Protein Engineering Design and Selection · doi:10.1093/protein/gzz046 · Cited by 30
Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease
Abskharon, R. N. N., Seidler, P. M., Sawaya, M. R., Cascio, D., Yang, T. P., Philipp, S., Williams, C. K., Newell, K. L., Ghetti, B. F., Deture, M. A., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013638 · Cited by 30
Expression and Endocytosis of Lysosomal Aspartylglucosaminidase in Mouse Primary Neurons
Kyttälä, A., Heinonen, O., Peltonen, L., & Jalanko, A. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-19-07750.1998 · Cited by 29
Single-domain antibody–based noninvasive in vivo imaging of α-synuclein or tau pathology
Jiang, Y., Lin, Y., Krishnaswamy, S., Pan, R., Wu, Q., Sandusky‐Beltran, L. A., Liu, M., Kuo, M., Kong, X., Congdon, E. E., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf3775 · Cited by 29
Estimation of polyclonal Ig G 4 hybrids in normal human serum
Young, E., Lock, E., Ward, D. G., Cook, A. M., Harding, S. J., & Wallis, G. L. F. (2014) · Immunology · doi:10.1111/imm.12265 · Cited by 28
Recruitment, Retainment, and Biomarkers of Response; A Pilot Trial of Lithium in Humans With Mild Cognitive Impairment
Duthie, A. C., van Aalten, L., Macdonald, C. F., McNeilly, A. D., Gallagher, J. E., Geddes, J. R., Lovestone, S., & Sutherland, C. D. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00163 · Cited by 28
The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant Klebsiella pneumoniae
Motley, M. P., Diago‐Navarro, E., Banerjee, K., Inzerillo, S., & Fries, B. C. (2020) · mBio · doi:10.1128/mbio.02059-20 · Cited by 28
Distinct phosphorylation profiles of tau in brains of patients with different tauopathies
Samimi, N., Sharma, G., Kimura, T., Matsubara, T., Huo, A., Chiba, K., Saito, Y., Murayama, S., Akatsu, H., Hashizume, Y., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.011 · Cited by 28
Membrane channel hypothesis of lysosomal permeabilization by beta-amyloid
Zaretsky, D. V., Zaretskaia, M. V., & Molkov, Y. I. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136338 · Cited by 28
Improved Tumor Localization and Radioimaging with Chemically Modified Monoclonal Antibodies
Khawli, L. A., Glasky, M. S., Alauddin, M. M., & Epstein, A. L. (1996) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1996.11.203 · Cited by 27
Fcγ receptors contribute to pyramidal cell death in the mouse hippocampus following local kainic acid injection
Suemitsu, S., Watanabe, M., Yokobayashi, E., Usui, S., Ishikawa, T., Matsumoto, Y., Yamada, N., Okamoto, M., & Kuroda, S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.004 · Cited by 27
Tau-targeting antibody therapies: too late, wrong epitope or wrong target?
Jabbari, E., & Duff, K. (2021) · Nature Medicine · doi:10.1038/s41591-021-01465-9 · Cited by 26
Alzheimer's therapy development: A few points to consider
Sigurdsson, E. M. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.001 · Cited by 25
Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development
Ng, P. Y., Chang, I. S., Koh, R. Y., & Chye, S. M. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00591-6 · Cited by 25
Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models
Krishnaswamy, S., Huang, H.-W., Marchal, I. S., Ryoo, H. D., & Sigurdsson, E. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104770 · Cited by 24
AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System
Marino, M., & Holt, M. G. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.870799 · Cited by 24
Intracellular accumulation of tau inhibits autophagosome formation by activating TIA1-amino acid-mTORC1 signaling
Li, M., Liu, E.-J., Zhou, Q., Li, S., Liu, S., Yu, H., Pan, Q., Sun, F., He, T., Wang, W.-J., et al. (2022) · Military Medical Research · doi:10.1186/s40779-022-00396-x · Cited by 24
Metabolic States Following Accumulation of Intracellular Aggregates: Implications for Neurodegenerative Diseases
Vázquez, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063822 · Cited by 23
cis pT231-Tau Drives Neurodegeneration in Bipolar Disorder
Naserkhaki, R., Zamanzadeh, S., Baharvand, H., Nabavi, S. M., Pakdaman, H., Shahbazi, S., Vosough, M., Ghaedi, G., Barzegar, A., Mirtorabi, D., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00629 · Cited by 23
Novel antibody against low‐n oligomers of tau protein promotes clearance of tau in cells via lysosomes
Chandupatla, R., Flatley, A., Feederle, R., Mandelkow, E., & Kaniyappan, S. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12097 · Cited by 23
Detecting tau in serum of transgenic animal models after tau immunotherapy treatment
d’Abramo, C., Acker, C. M., Schachter, J. B., Terracina, G., Wang, X., Forest, S. K., & Davies, P. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.017 · Cited by 22
Evidence that Brain-Reactive Autoantibodies Contribute to Chronic Neuronal Internalization of Exogenous Amyloid-β1-42 and Key Cell Surface Proteins During Alzheimer’s Disease Pathogenesis
Goldwaser, E. L., Acharya, N. K., Wu, H., Godsey, G. A., Sarkar, A., DeMarshall, C. A., Kosciuk, M. C., & Nagele, R. G. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190962 · Cited by 22
Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer’s Disease
Bhatia, S., Singh, M., Singh, T., & Singh, V. (2023) · Neurochemical Research · doi:10.1007/s11064-022-03722-w · Cited by 22
Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimer’s Disease and Primary Tauopathy Postmortem Brains
Helboe, L., Rosenqvist, N., Volbracht, C., Pedersen, L. Ø., Pedersen, J. T., Christensen, S., Egebjerg, J., Christoffersen, C. T., Bang‐Andersen, B., Beach, T. G., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220125 · Cited by 20
Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation
Wu, L., Gilyazova, N., Ervin, J. F., Wang, S. J., & Xu, B. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00342 · Cited by 20
Dynamics of Internalization and Intracellular Interaction of Tau Antibodies and Human Pathological Tau Protein in a Human Neuron-Like Model
Shamir, D. B., Deng, Y., Wu, Q., Modak, S., Congdon, E. E., & Sigurdsson, E. M. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.602292 · Cited by 19
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab
Koga, S., Dickson, D. W., & Wszołek, Z. K. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00283-0 · Cited by 19
Administration of AAV-Alpha Synuclein NAC Antibody Improves Locomotor Behavior in Rats Overexpressing Alpha Synuclein
Chen, Y., Wu, K., Hsieh, W., Harvey, B. K., Hoffer, B. J., Wang, Y., & Yu, S. (2021) · Genes · doi:10.3390/genes12060948 · Cited by 18
Pathogenic cis p-tau levels in CSF reflects severity of traumatic brain injury
Sisakht, A. M., Ziarati, N. K., Jahanbakhshi, A., Shahpasand, K., Aghababaei, S., Ahmadvand, O., Azar, M., Fattahi, A., & Zamanzadeh, S. (2022) · Neurological Research · doi:10.1080/01616412.2021.2022921 · Cited by 18
Effect of tau-pathology on charged multivesicular body protein 2b (CHMP2B)
Midani-Kurçak, J. S., Dinekov, M., Puladi, B., Arzberger, T., & Köhler, C. N. (2018) · Brain Research · doi:10.1016/j.brainres.2018.11.008 · Cited by 17
Increased neuronal activity in motor cortex reveals prominent calcium dyshomeostasis in tauopathy mice
Wu, Q., Bai, Y., Li, W., Congdon, E. E., Liu, W., Lin, Y., Ji, C., Gan, W., & Sigurdsson, E. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105165 · Cited by 15
Association of Tau Pathology With Clinical Symptoms in the Subfields of Hippocampal Formation
Ge, X., Zhang, D., Qiao, Y., Zhang, J., Xu, J., & Zheng, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.672077 · Cited by 15
The tau oligomer antibody APNmAb005 detects early-stage pathological tau enriched at synapses and rescues neuronal loss in long-term treatmentsPreprint
Tai, H., Ma, H.-T., Huang, S.-C., Wu, M., Wu, C., Lai, Y., Li, Z., Margolin, R. A., Intorcia, A. J., Serrano, G. E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.24.497452 · Cited by 15
A phase 1b open‐label study of sodium selenate as a disease‐modifying treatment for possible behavioral variant frontotemporal dementia
Vivash, L. E., Malpas, C. B., Meletis, C., Gollant, M., Eratne, D., Li, Q., McDonald, S. J., O’Brien, W. T., Brodtmann, A. G., Darby, D., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12299 · Cited by 15
Insoluble Tau From Human FTDP-17 Cases Exhibit Unique Transmission Properties In Vivo
Weitzman, S. A., Narasimhan, S., He, Z., Changolkar, L. N., McBride, J. D., Zhang, B., Schellenberg, G. D., Trojanowski, J. Q., & Lee, V. M. ‐. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa086 · Cited by 14
A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia
Vivash, L. E., Malpas, C. B., Churilov, L. P., Walterfang, M., Brodtmann, A. G., Piguet, O., Ahmed, R. M., Bush, A. I., Hovens, C. M., Kalinčík, T., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040100 · Cited by 14
A call for better understanding of target engagement in Tau antibody development
Bespalov, A., Courade, J., Khiroug, L., Terstappen, G. C., & Wang, Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103338 · Cited by 13
[O2–17–03]: A PHASE I STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RO7105705 IN HEALTHY VOLUNTEERS AND PATIENTS WITH MILD‐TO‐MODERATE AD
Kerchner, G. A., Ayalon, G., Brunstein, F., Chandra, P., Datwani, A., Fuji, R. N., Manser, P. T., Vaze, A., Ward, M. R., Wildsmith, K. R., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.07.243 · Cited by 12
Conformational change and GTPase activity of human tubulin: A comparative study on Alzheimer’s disease and healthy brain
Rajaei, S., Karima, S., Tehrani, H. S., Shateri, S., Baram, S. M., Mahdavi, M., Mokhtari, F., Alimohammadi, A., Tafakhori, A., Amiri, A., et al. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15009 · Cited by 12
Downregulation of α-Synuclein Protein Levels by an Intracellular Single-Chain Antibody
Chen, Y., Yu, S., Wu, K., Wang, Y.-S., Tsai, H.-M., Liao, L.-W., Chen, S., Hsieh, W., Chen, H., Hsu, S., et al. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-191787 · Cited by 12
Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial
Vivash, L. E., Bertram, K., Malpas, C. B., Marotta, C., Harding, I. H., Kolbe, S., Fielding, J., Clough, M., Lewis, S. J. G., Tisch, S. H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-055019 · Cited by 12
A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O‐GlcNAcase (OGA) enzyme
Kielbasa, W., Phipps, K. M., Tseng, J., Natanegara, F., Cheng, E. Y. J., Monk, S. A., Bundgaard, C., Donnelly, K. B., Nuthall, H. N., McDonald, N., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.040473 · Cited by 11
Tau immunotherapy in Alzheimer’s disease and progressive supranuclear palsy
Karimi, N., Catak, F. B., Arslan, E. O., Saghazadeh, A., & Rezaei, N. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109445 · Cited by 11
In Vivo Imaging of Tauopathy in Mice
Krishnaswamy, S., Wu, Q., Lin, Y., Rajamohamedsait, W. J., Rajamohamedsait, H. B., & Sigurdsson, E. M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7816-8_32 · Cited by 10
Inhibition of caspase-1 ameliorates tauopathy and rescues cognitive impairment in SAMP8 mice
Tan, M.-S., Liu, Y., Hu, H., Tan, C.-C., & Tan, L. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-00914-9 · Cited by 10
Common and Specific Marks of Different Tau Strains Following Intra-Hippocampal Injection of AD, PiD, and GGT Inoculum in hTau Transgenic Mice
Ferrer, I., Andrés‐Benito, P., Carmona, M., & del Rı́o, J. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415940 · Cited by 10
Nonsteroidal anti-inflammatory drugs and paracetamol in children.
Camu, F., de Velde, A. V., & Vanlersberghe, C. (2001) · PubMed · Cited by 9
Selective uptake by Purkinje neurons of antibodies to S-100 protein
Karpiak, S. E., & Mahadik, S. P. (1987) · Experimental Neurology · doi:10.1016/0014-4886(87)90254-8 · Cited by 9
A Single-Chain Variable Fragment Antibody Inhibits Aggregation of Phosphorylated Tau and Ameliorates Tau Toxicity in vitro and in vivo
Li, S., Yi, Y., Cui, K., Zhang, Y., Chen, Y., Han, D., Sun, L. V., Zhang, X., Chen, F., Zhang, Y., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-191266 · Cited by 9
Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers
Kielbasa, W., Shcherbinin, S., Goldsmith, P., Phipps, K. M., Biglan, K., Mancini, M., Russell, D., Constantinescu, C. C., Gunn, R. N., Nuthall, H. N., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.057774 · Cited by 9
Distribution and Expression of the α-Tubulin mRNA in the Hippocampus and the Temporal Cortex in Alzheimer's Diseases
Brion, J., & Flament-Durand, J. (1995) · Pathology - Research and Practice · doi:10.1016/s0344-0338(11)80867-8 · Cited by 8
O2–05–04: Tau–based immunotherapy for dementia
Asuni, A. A., Quartermain, D., & Sigurdsson, E. M. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.141 · Cited by 8
Single and multiple ascending dose studies in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme
Lowe, S. L., Goldsmith, P., Phipps, K. M., Donnelly, K. B., Biglan, K., Mancini, M., Nuthall, H. N., Mergott, D. J., & Kielbasa, W. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.057728 · Cited by 5
Efficacy of the murine version of E2814 in a validated AD brain seed‐injection model in hTau mice
Talma, S., Gartlon, J. E., Takahashi, E., Horie, K., Wildsmith, K. R., Staddon, J. M., de Silva, R., & Roberts, M. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.076853 · Cited by 2
Neuroinflammation co‐localizes highly with tau in amnestic mild cognitive impairment
Appleton, J., Funk, Q., Bradbury, K., Yu, M., Faridar, A., Beers, D. R., Appel, S. H., Fujita, M., Masdeu, J. C., & Pascual, B. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.068025 · Cited by 1
Untitled work
(1997) · doi:10.1002/(sici)1097-4547(19970415)48:2
Untitled work
(1998) · doi:10.1002/(sici)1097-4547(19980615)52:6

Research works printed but not linked: 19

Alzforum. Antisense therapy stifles CSF tau in mild Alzheimer’s disease. Alzforum https://www.alzforum.org/news/conference-coverage/antisense-therapy-stifles-csf-tau-mild-alzheimers-disease-0 (2021).
Alzforum. First hit on aggregated tau: antisense oligonucleotide lowers tangles. Alzforum https://www.alzforum.org/news/conference-coverage/first-hit-aggregated-tau-antisense-oligonucleotide-lowers-tangles (2023).
Ryan, J. M. et al. Phase 1 study in healthy volunteers of the O-GlcNAcase inhibitor ASN120290 as a novel therapy for progressive supranuclear palsy and related tauopathies [abstract O1-12-05]. Alzheimers Dement. 14 (7S Part 4), 251 (2018).
Shcherbinin, S. et al. Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: translation from rat to human: neuroimaging/evaluating treatments. Alzheimers Dement. 16, e040558 (2020).
Alzforum. Tau inhibitor fails again – subgroup analysis irks clinicians at CTAD. Alzforum https://www.alzforum.org/news/conference-coverage/tau-inhibitor-fails-again-subgroup-analysis-irks-clinicians-ctad (2016).
Alzforum. In first phase 3 trial, the Tau drug LMTM did not work. Period. Alzforum http://www.alzforum.org/news/conference-coverage/first-phase-3-trial-tau-drug-lmtm-did-not-work-period#show-more (2016).
Alzforum. First round of FTD therapeutics fell short, but many more are up and running. Alzforum https://www.alzforum.org/news/conference-coverage/first-round-ftd-therapeutics-fell-short-many-more-are-and-running (2016).
Boutajangout, A., Ingadottir, J., Davies, P. & Sigurdsson, E. M. Passive tau immuntherapy diminishes functional decline and clears tau aggregates in a mouse model of tauopathy [abstract P3-427]. Alzheimers Dement. 6 (4S Part 19), S578 (2010).
Alzforum. Active tau vaccine: hints of slowing neurodegeneration. Alzforum https://www.alzforum.org/news/conference-coverage/active-tau-vaccine-hints-slowing-neurodegeneration (2020).
UCB. UCB presents UCB0107 anti-Tau immunotherapy Phase I study Results at World Movement Disorders Conference®. UCB https://www.ucb.com/stories-media/Press-Releases/article/UCB-presents-UCB0107-anti-Tau-immunotherapy-Phase-I-study-results-at-World-Movement-Disorders-Conference (2019).
Alzforum. N-terminal tau antibodies fade, mid-domain ones push to the fore. Alzforum https://www.alzforum.org/news/conference-coverage/n-terminal-tau-antibodies-fade-mid-domain-ones-push-fore (2021).
Alzforum. More tau antibodies bid adieu; semorinemab keeps foot in door. Alzforum https://www.alzforum.org/news/conference-coverage/more-tau-antibodies-bid-adieu-semorinemab-keeps-foot-door (2021).
Eisai. Eisai presents data showing quantification of tau microtubule binding region in cerebrospinal fluid and the identification of a target engagement biomarker for the new anti-tau antibody E2814 at Alzheimer’s Association International Conference (AAIC) 2019. Eisai https://www.eisai.com/news/2019/news201955.html (2019).
Horie, K. et al. Quantification of the tau microtubule binding region (MTBR) in cerebrospinal fluid and subsequent validation of target engagement assay for E2814, a novel anti-tau therapeutic antibody. Alzheimers Dement. 15(7S Part 31), 1598–1599 (2019).
Zhou, J. et al. E2814: an anti-tau therapy engages its CNS target and affects the downstream tangle-specific biomarker MTBR-tau243 in dominantly inherited Alzheimer’s disease [abstract]. Presented at the Alzheimer’s Association International Conference, Amsterdam, Netherlands, and Online 2023 (2023).
Rawal, S. et al. Safety, pharmacokinetics and immunogenicity of single and multiple ascending doses of the anti-tau therapeutic antibody E2814: a phase 1, first-in-human (FIH) study in healthy subjects [abstract P1-909]. Presented at the Alzheimer’s Association International Conference, Amsterdam, Netherlands, and Online (2023).
Galpern, W. R. et al. A single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-phospho-tau antibody JNJ-63733657 in healthy subjects [abstract P1-052]. Alzheimers Dement. 15 (7S Part 5), 252–253 (2019).
Prothena. Prothena reports topline phase 1 single ascending dose study results of PRX005, a novel anti-MTBR-tau antibody for the potential treatment of Alzheimer’s disease. Prothena https://ir.prothena.com/investors/press-releases/news-details/2023/Prothena-Reports-Topline-Phase-1-Single-Ascending-Dose-Study-Results-of-PRX005-a-Novel-Anti-MTBR-Tau-Antibody-for-the-Potential-Treatment-of-Alzheimers-Disease/default.aspx (2023).
Martenyi, F. et al. PRX005, a novel anti-MTBR tau monoclonal antibody: results from a first-in-human double-blind, placebo-controlled, single ascending dose phase 1 study [abstract P1-727]. Presented at the Alzheimer’s Association International Conference, Amsterdam, Netherlands, and Online (2023).

Sorted by citations

Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2024) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 483
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis
Terao, I., & Kodama, W. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102203 · Cited by 137
Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies
Zhang, X., Wang, J., Zhang, Z., & Ye, K. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00429-6 · Cited by 119
Pathological mechanisms and treatment progression of Alzheimer’s disease
Zhang, J., Kong, G., Yang, J., Pang, L., & Li, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02886-9 · Cited by 111

See all 372

Authors: Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M.
Affiliations: New York University (US)
NYU Langone Health (US)
Corresponding author: Sigurdsson, Einar M.
ORCID: Congdon, Erin E.
Ji, Changyi
Tetlow, Amber M.
Jiang, Yixiang
Sigurdsson, Einar M.
Venue: Nature Reviews Neurology
Publisher: Springer Science and Business Media LLC
Published: 2023-10-24
Volume: 19
Issue: 12
Pages: 715-736
ISSN: 1759-4758 (ISSN-L)
1759-4766
DOI: 10.1038/s41582-023-00883-2
PMC: PMC10965012
OpenAlex: W4387904363
Cited by: 371
References: 380
Citations by year: 2026: 125 · 2025: 170 · 2024: 74 · 2023: 1
FWCI: 13.17
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Neurology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Alzheimer's Association (AG032611, AARF-22-924783)
National Institutes of Health (NS120488)
National Institute on Aging (R21AG069475, R01AG032611, T32AG052909)
National Institute of Neurological Disorders and Stroke (RF1NS120488, R01NS120488, R01NS077239)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, tau protein, tau immunotherapy, tau aggregation, microtubule stabilization, post-translational modification, amyloid plaques, neurofibrillary tangles, clinical trials, drug candidates
MeSH terms: Aged, Alzheimer Disease, Humans, Immunotherapy, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tau-targeting therapies for Alzheimer disease: current status and future directions

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks